Potential Drug for Primary Mitochondrial Myopathy Granted FDA Fast-Track Status
The U.S. Food and Drug Administration (FDA) has granted Boston-based Stealth BioTherapeutics Fast Track designation for its MTP-131 (also known as Bendavia) for the treatment of primary mitochondrial myopathy. Genetic mitochondrial diseases are a group of rare inherited disorders generally characterized by systemic mitochondrial dysfunction, impairing patients’ health and well-being. It…